Visterra to Present Data on VIS513, its Humanised mAb That Targets a Conserved Site on the Dengue Virus E Protein
Visterra, Inc., a biotechnology company that uses its proprietary technology platform to identify unique disease targets and design novel therapeutics, has announced that new preclinical data for VIS513 will be presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Washington DC.
“VIS513 was developed using Visterra’s innovative and proprietary technology and we are very encouraged by these new data which show the potential of VIS513 to broadly neutralise all four dengue virus serotypes,” said Brian J.G. Pereira, MD, President and Chief Executive Officer of Visterra. “Currently there is no specific treatment for dengue and prevention depends solely on limiting or eradicating mosquitoes that transmit the virus. VIS513 has demonstrated a rapid reduction in viral titers after a single systemic administration, which supports its potential use as a treatment for dengue virus infection. Based on these data, we plan to advance its development and enter the clinic in 2015.”
The poster presentation scheduled for ICAAC is: “Design of a Broadly Neutralizing Antibody Targeting Dengue Virus E Protein Domain III,” [V-1819]
Monday, 8 September 2014, 11:00 am–1:00 pm, Poster Session Respiratory and Other Viruses: Novel Treatments, Resistance, and Clinical Observations (Exhibit Hall B/Walter E. Washington Convention Center)
Related News
-
News CPHI Podcast Series: the power of digital marketing in pharma
Digital marketing is a valuable tool for many industries, and the pharmaceutical and healthcare industry is no exception. The CPHI Podcast Series covers how marketing can be used by companies to increase their engagement and overcome challenges.&n... -
News Novel approach to creating sustainable packaging from rice husks
Researchers have created a new approach to the designing of eco-friendly nanofibres extracted from rice husks, addressing the critical need for sustainable packaging materials in food and biopharmaceutical products. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance